MX360098B - Conjugados dirigidos encapsulados en partículas y sus formulaciones. - Google Patents
Conjugados dirigidos encapsulados en partículas y sus formulaciones.Info
- Publication number
- MX360098B MX360098B MX2015008503A MX2015008503A MX360098B MX 360098 B MX360098 B MX 360098B MX 2015008503 A MX2015008503 A MX 2015008503A MX 2015008503 A MX2015008503 A MX 2015008503A MX 360098 B MX360098 B MX 360098B
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- particles
- methods
- targeted conjugates
- active agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Abstract
La presente invención se refiere a partículas, incluyendo nanopartículas y micropartículas, y sus formulaciones farmacéuticas que contienen conjugados de un agente activo como un agente terapéutico, profiláctico o diagnóstico unido a una fracción dirigida por medio de un linker. Las partículas diseñadas proveen una liberación tempo-espacial mejorada del agente activo y/o una biodistribución mejorada. Los métodos para hacer los conjugados, las partículas, y sus formulaciones son proveídos. Los métodos para administrar las formulaciones a sujetos que las requieran son proveídos, por ejemplo, para tratar o prevenir cáncer o enfermedades infecciosas. Uso de la nanopartícula polimérica de liberación controlada en la fabricación de un medicamento para reducir el volumen tumoral en un sujeto que lo necesita.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261746866P | 2012-12-28 | 2012-12-28 | |
PCT/US2013/078361 WO2014106208A1 (en) | 2012-12-28 | 2013-12-30 | Targeted conjugates encapsulated in particles and formulations thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015008503A MX2015008503A (es) | 2016-01-22 |
MX360098B true MX360098B (es) | 2018-10-22 |
Family
ID=49998713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008503A MX360098B (es) | 2012-12-28 | 2013-12-30 | Conjugados dirigidos encapsulados en partículas y sus formulaciones. |
Country Status (14)
Country | Link |
---|---|
US (5) | US20140187501A1 (es) |
EP (1) | EP2938364A1 (es) |
JP (2) | JP6118914B2 (es) |
KR (1) | KR20150100706A (es) |
CN (2) | CN104936622B (es) |
AU (2) | AU2013369982B2 (es) |
CA (1) | CA2896571C (es) |
HK (1) | HK1217085A1 (es) |
IL (1) | IL238994B (es) |
MX (1) | MX360098B (es) |
MY (1) | MY172519A (es) |
SG (2) | SG10201705514WA (es) |
WO (1) | WO2014106208A1 (es) |
ZA (1) | ZA201504109B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE047200T2 (hu) | 2007-08-17 | 2020-04-28 | Purdue Research Foundation | PSMA kötõ ligandum-linker konjugátumok és azok alkalmazási módszerei |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
JP6892218B2 (ja) | 2012-11-15 | 2021-06-23 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 薬物送達結合体およびpsma発現細胞によって引き起こされる疾患の治療方法 |
US20140187501A1 (en) * | 2012-12-28 | 2014-07-03 | Blend Therapeutics, Inc. | Targeted Conjugates Encapsulated in Particles and Formulations Thereof |
PE20160678A1 (es) | 2013-10-18 | 2016-08-06 | Deutsches Krebsforsch | Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata |
US10011622B2 (en) * | 2013-12-31 | 2018-07-03 | Placon Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of cancers |
CA2969263C (en) * | 2014-12-01 | 2022-11-29 | Innoup Farma, S.L. | Nanoparticles for encapsulating compounds, the preparation and uses thereof |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
EP3265063A4 (en) | 2015-03-03 | 2018-11-07 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
EP3265059A4 (en) | 2015-03-03 | 2018-08-29 | Cureport Inc. | Combination liposomal pharmaceutical formulations |
CA2988591A1 (en) * | 2015-06-30 | 2017-01-05 | Tarveda Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
AU2016303497A1 (en) * | 2015-07-31 | 2018-03-01 | Tarveda Therapeutics, Inc. | Compositions and methods for immuno-oncology therapies |
EP3353309A4 (en) * | 2015-09-25 | 2019-04-10 | Tarveda Therapeutics, Inc. | COMPOSITIONS AND METHOD FOR GENERIC EDITING |
PE20181350A1 (es) | 2015-09-30 | 2018-08-22 | Deutsches Krebsforsch | Inhibidores marcados con 18f mejorados de antigeno de membrana especifico de prostata (psma) y su uso como agentes de diagnostico por imagenes para el cancer de prostata |
WO2017062657A1 (en) | 2015-10-06 | 2017-04-13 | University Of Wahsington | Oxygen reactive polymers for treatment of traumatic brain injury |
JP7057278B2 (ja) | 2015-10-28 | 2022-04-19 | ターベダ セラピューティクス インコーポレイテッド | Sstr標的化コンジュゲート及び粒子並びにその製剤 |
CN106957422B (zh) * | 2015-12-31 | 2020-07-07 | 南京绿叶制药有限公司 | 一种磷脂-聚乙二醇-psma配体化合物及其制备方法 |
US10548881B2 (en) | 2016-02-23 | 2020-02-04 | Tarveda Therapeutics, Inc. | HSP90 targeted conjugates and particles and formulations thereof |
US10744212B2 (en) * | 2016-03-14 | 2020-08-18 | General Electric Company | Topical application of nerve labeling dyes for image-guided surgery |
US11280766B2 (en) | 2016-07-28 | 2022-03-22 | Waters Technologies Corporation | Encapsulated pre-analytic workflows for flow-through devices, liquid chromatography and mass spectrometric analysis |
WO2018022957A1 (en) * | 2016-07-29 | 2018-02-01 | Tarveda Therapeutics, Inc. | T cell binding conjugates and methods of use |
AU2017376766A1 (en) * | 2016-12-14 | 2019-06-06 | Tva (Abc), Llc | HSP90-targeting conjugates and formulations thereof |
BR112019015145A2 (pt) * | 2017-01-24 | 2020-03-24 | Société des Produits Nestlé S.A. | Composições que compreendem anticorpos anti-fel d1 e métodos para reduzir pelo menos um sintoma da alergia de humanos a gatos |
WO2019023295A1 (en) * | 2017-07-27 | 2019-01-31 | Saint Louis University | HUMAN EPIDERMAL GROWTH FACTOR MODIFIED BY FATTY ACID |
US20190231690A1 (en) * | 2017-11-08 | 2019-08-01 | L.E.A.F. Holdings Group Llc | Platinum complexes and uses thereof |
CN112272519B (zh) * | 2018-05-27 | 2023-01-06 | 以色列国家农业部、农村发展农业研究组织 | 用于生物杀虫剂的经由皮克林乳液的单个单元体封装 |
JP2021527675A (ja) * | 2018-06-21 | 2021-10-14 | ナノメッド ホールディングス プロプライエタリー リミテッド | プラチナベースの両親媒性プロドラッグ |
US20210244822A1 (en) * | 2018-06-25 | 2021-08-12 | The Board Of Regents Of The University Of Oklahoma | Conjugates with internal and terminal-end heparosan linkages |
EP3846857A4 (en) | 2018-09-04 | 2022-10-12 | The Board Of Regents Of The University Of Texas System | COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS |
AU2019336679A1 (en) | 2018-09-04 | 2021-03-25 | The Board Of Regents Of The University Of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
CN109289053B (zh) * | 2018-09-30 | 2020-10-13 | 浙江大学 | 卡巴他赛-寡/聚乳酸偶联前药、制剂及其制备方法与应用 |
CA3143373A1 (en) * | 2019-06-25 | 2020-12-30 | Tarveda Therapeutics, Inc. | Sstr-targeted conjugates and formulations thereof |
CN110974972B (zh) * | 2019-12-03 | 2023-01-20 | 沈阳药科大学 | 难溶性药物的弱酸性衍生物及其脂质体制剂 |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
KR20210116339A (ko) * | 2020-03-16 | 2021-09-27 | 주식회사 바이오이즈 | 표적화 압타머 접합체를 캡슐화한 입자 및 이의 용도 |
CN111888332B (zh) * | 2020-06-19 | 2023-07-25 | 杭州师范大学 | 一种卡巴他赛柔性乳剂及其制备方法 |
US11896713B2 (en) * | 2020-10-22 | 2024-02-13 | Rutgers, The State University Of New Jersey | Strategies to enhance lung cancer treatment |
CN113087787B (zh) * | 2021-05-19 | 2023-03-21 | 广西医科大学第二附属医院(广西医科大学第二临床医学院) | 一种蚯蚓血红蛋白分离及纯化方法 |
EP4282435A1 (en) * | 2022-05-23 | 2023-11-29 | Danmarks Tekniske Universitet | Formulations of active pharmaceutical ingredients and excipients in icells via hydrophobic ion pairing |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030049203A1 (en) * | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
US20030109682A1 (en) * | 2001-09-07 | 2003-06-12 | Daniel Santi | Maytansines and maytansine conjugates |
CA2504268A1 (en) * | 2002-10-30 | 2004-11-18 | Spherics, Inc. | Nanoparticulate bioactive agents |
US7232805B2 (en) * | 2003-09-10 | 2007-06-19 | Inflabloc Pharmaceuticals, Inc. | Cobalamin conjugates for anti-tumor therapy |
WO2005118612A1 (en) * | 2004-06-04 | 2005-12-15 | Sonus Pharmaceuticals, Inc. | Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs |
DK2258376T3 (en) * | 2004-07-27 | 2019-04-15 | Gilead Sciences Inc | Phosphonate analogues of HIV inhibitor compounds |
EP1700608A1 (en) * | 2005-03-10 | 2006-09-13 | Schering AG | Chelators for radioactively labeled conjugates comprising a stabilizing sidechain |
EP1745802A1 (en) * | 2005-07-20 | 2007-01-24 | Kreatech Biotechnology B.V. | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
CA2652280C (en) * | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
EP2436376B1 (en) * | 2007-09-28 | 2014-07-09 | BIND Therapeutics, Inc. | Cancer cell targeting using nanoparticles |
RU2505544C2 (ru) * | 2007-10-19 | 2014-01-27 | Дженентек, Инк. | Антитела против tenb2, сконструированные с цистеином, и конъюгаты антитело - лекарственное средство |
CN102099059B (zh) * | 2008-06-13 | 2015-09-23 | 西塞医疗中心 | 用于癌症靶向治疗的小分子配体-药物轭合物 |
US20110105417A1 (en) * | 2008-06-26 | 2011-05-05 | The Curators Of The University Of Missouri | Drug Conjugates |
WO2010047765A2 (en) * | 2008-10-20 | 2010-04-29 | Massachussetts Institute Of Technology | Nanostructures for drug delivery |
IN2012DN03025A (es) * | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
KR102416359B1 (ko) * | 2010-04-15 | 2022-07-01 | 코디악 사이언시스 인코포레이티드 | 고분자량 쌍성이온-함유 중합체 |
WO2012030745A1 (en) * | 2010-08-30 | 2012-03-08 | Access Pharmaecuticals, Inc | MULTIVITAMIN TARGETING OF RNAi THERAPEUTICS |
FR2967581B1 (fr) * | 2010-11-19 | 2012-12-28 | Sanofi Aventis | Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques |
RU2612017C2 (ru) * | 2011-04-07 | 2017-03-01 | Де Скриппс Рисерч Инститьют | Высокопроизводительный скрининг соединений, модулирующих экспрессию клеточных макромолекул |
US20140308363A1 (en) * | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US20140187501A1 (en) * | 2012-12-28 | 2014-07-03 | Blend Therapeutics, Inc. | Targeted Conjugates Encapsulated in Particles and Formulations Thereof |
-
2013
- 2013-12-30 US US14/144,263 patent/US20140187501A1/en not_active Abandoned
- 2013-12-30 AU AU2013369982A patent/AU2013369982B2/en not_active Ceased
- 2013-12-30 WO PCT/US2013/078361 patent/WO2014106208A1/en active Application Filing
- 2013-12-30 KR KR1020157017269A patent/KR20150100706A/ko not_active Application Discontinuation
- 2013-12-30 CN CN201380068680.4A patent/CN104936622B/zh not_active Expired - Fee Related
- 2013-12-30 CN CN201910388193.5A patent/CN110179995A/zh active Pending
- 2013-12-30 EP EP13822073.6A patent/EP2938364A1/en not_active Withdrawn
- 2013-12-30 SG SG10201705514WA patent/SG10201705514WA/en unknown
- 2013-12-30 JP JP2015550852A patent/JP6118914B2/ja not_active Expired - Fee Related
- 2013-12-30 CA CA2896571A patent/CA2896571C/en active Active
- 2013-12-30 SG SG11201504235UA patent/SG11201504235UA/en unknown
- 2013-12-30 MX MX2015008503A patent/MX360098B/es active IP Right Grant
- 2013-12-30 MY MYPI2015001403A patent/MY172519A/en unknown
-
2015
- 2015-05-25 IL IL238994A patent/IL238994B/en active IP Right Grant
- 2015-06-08 ZA ZA201504109A patent/ZA201504109B/en unknown
- 2015-11-23 US US14/949,138 patent/US20160074526A1/en not_active Abandoned
-
2016
- 2016-04-26 HK HK16104731.8A patent/HK1217085A1/zh unknown
-
2017
- 2017-01-25 AU AU2017200510A patent/AU2017200510A1/en not_active Abandoned
- 2017-03-27 JP JP2017060849A patent/JP2017105855A/ja active Pending
- 2017-09-05 US US15/695,214 patent/US20180021454A1/en not_active Abandoned
-
2019
- 2019-12-20 US US16/722,913 patent/US20200121808A1/en not_active Abandoned
-
2022
- 2022-05-23 US US17/750,865 patent/US20220288229A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2896571C (en) | 2017-11-21 |
US20140187501A1 (en) | 2014-07-03 |
AU2017200510A1 (en) | 2017-02-16 |
US20200121808A1 (en) | 2020-04-23 |
CN104936622A (zh) | 2015-09-23 |
US20180021454A1 (en) | 2018-01-25 |
AU2013369982B2 (en) | 2016-11-17 |
AU2013369982A1 (en) | 2015-06-18 |
HK1217085A1 (zh) | 2016-12-23 |
IL238994B (en) | 2019-07-31 |
CA2896571A1 (en) | 2014-07-03 |
SG11201504235UA (en) | 2015-07-30 |
ZA201504109B (en) | 2019-10-30 |
US20160074526A1 (en) | 2016-03-17 |
MY172519A (en) | 2019-11-28 |
WO2014106208A1 (en) | 2014-07-03 |
JP2017105855A (ja) | 2017-06-15 |
SG10201705514WA (en) | 2017-08-30 |
EP2938364A1 (en) | 2015-11-04 |
IL238994A0 (en) | 2015-07-30 |
US20220288229A1 (en) | 2022-09-15 |
CN110179995A (zh) | 2019-08-30 |
JP6118914B2 (ja) | 2017-04-19 |
KR20150100706A (ko) | 2015-09-02 |
CN104936622B (zh) | 2019-05-28 |
MX2015008503A (es) | 2016-01-22 |
JP2016505609A (ja) | 2016-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015008503A (es) | Conjugados dirigidos encapsulados en particulas y sus formulaciones. | |
PH12017500023A1 (en) | Targeted conjugates and particles and formulations thereof | |
EA033456B1 (ru) | Конъюгаты антитело-лекарственное средство, содержащие пептидомиметические линкеры | |
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
PH12016501171A1 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
MX2010003642A (es) | Nanotecnologia de vacuna. | |
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
NZ710746A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
WO2012129112A3 (en) | Use of intracellular enzymes for the release of covalently linked bioactives | |
NZ710729A (en) | Amatoxin derivatives | |
IN2015DN03219A (es) | ||
MX341332B (es) | Lipidos biodegradables para la administracion de agentes activos. | |
IN2012DN06720A (es) | ||
MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
UA104320C2 (ru) | Фармацевтическая композиция на основе митохондриально-адресованного антиоксиданта для применения в медицинской и ветеринарной офтальмологии | |
PH12017502392A1 (en) | Targeted conjugates and particles and formulations thereof | |
WO2011002852A3 (en) | Pro-drug complexes and related methods of use | |
IN2014DN09418A (es) | ||
EP3001813A4 (en) | Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging | |
WO2017210246A3 (en) | Penicillamine conjugates and particles and formulations thereof | |
WO2012009703A3 (en) | Targeted nanoparticles for cancer and other disorders | |
MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
MX2019004963A (es) | Conjugados y particulas especificos del sstr y formulaciones de los mismos. | |
TR201109804A2 (tr) | Tek dozlu inhalasyon cihazı. | |
WO2012177653A3 (en) | Targeting the neuromuscular junction for treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: WALMART APOLLO, LLC |
|
FG | Grant or registration |